Three Billion, an artificial intelligence rare disease company, announced on the 11th that its sales doubled last year compared to the previous year, leveraging its global growth.
Based on the pre-audit preliminary settlement, Three Billion recorded sales of 5.8 billion KRW last year, an increase of 112% compared to the previous year.
Following a threefold increase in sales in 2023 compared to the previous year, the company continued to grow rapidly last year.
Last year's operating loss was 7.4 billion KRW, slightly down from 8.4 billion KRW the previous year. Employment growth and facility investments continued to support this growth.
The rare disease genetic testing service showed steady growth in over 70 countries worldwide, driving Three Billion's sales growth. The company's overseas sales ratio exceeds 70%. The company explained that the customer repurchase rate is as high as 80%, indicating strong trust.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
